High Tide Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY Revenue (est.)
$523.2Mnext fiscal year
FY EPS (est.)
$0.04next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fourth Fiscal Quarter and Full Year 2026 Financial Results | 28 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Canna Cabana Store Count Quarterly228Target: Exceed 350 locations nationwide
Cabana Club Membership Quarterly2.7M
ELITE Paid Membership Quarterly178K
Remexian German Medical Cannabis Distribution Volume (Tonnes) Quarterly7.6
Watch Items
- Same-Store Sales Growth PressureTrigger: Same-store sales growth falling below -2.0% sequentially or year-over-yearAction: Re-evaluate discount club pricing tiers, optimize local marketing, and accelerate high-margin white-label product rollouts.
- German Medical Cannabis Regulatory ChangesTrigger: Any tightening of import quotas or changes to pharmacy distribution laws in GermanyAction: Leverage Remexian's global sourcing licenses (19 countries) to shift supply chains and protect distribution margins.
- U.S. Federal Cannabis Reform (Rescheduling/280E)Trigger: Official DEA rescheduling of cannabis to Schedule IIIAction: Activate expansion plans for U.S. CBD subsidiaries (NuLeaf Naturals and FAB CBD) and evaluate brick-and-mortar entry strategies.
Research as of 20 Jun 2026